PI: Claire Monge & Bernard Verrier
In recent years, nanodelivery systems have raised huge interest as platforms for drug delivery or vaccine development, as they offer multiple options for improving the safety and efficacy of therapeutic agents. For example, side effects might be decreased upon encapsulation of drugs or adjuvants. Although the use of nanodelivery systems has open a wide area of research in nanomedicine, it should be implemented with caution as their safety is a main issue.
We are focusing our work in this field on three aspects :
i) Elaborate innovative particles and delivery systems, using ecocompatible strategies and a dual delivery concept
ii) Decipher the in vivo biodistribution and fate of particles, using mice or zebrafish models
iii) Develop therapeutic formulations based on dual delivery systems, using innate immunity knowledge to target specific types of immune responses, such as mucosal immunity or targeted cytotoxic effect.
Our general objective is to bring innovative scientific information to increase efficiency and safety of therapeutic engineering based on biodegradable dual delivery systems.
As therapeutic challenges, we focus our work on infectious diseases targeting mucosa (HIV-1 and Influenza), with a strong emphasis on designing therapeutic formulations able to cross biological barriers.
Key-words: nanovector, nanomaterial, biodegradable polymer, vaccine, drug delivery, adjuvant, skin, mucosae, biodistribution
Equipe Vecteurs colloïdaux et ingénierie thérapeutique ciblée
Laboratoire de Biologie Tissulaire et Ingénierie thérapeutique – CNRS – UMR 5305 – University Claude Bernard Lyon 1
Institut de Biologie et Chimie des Protéines
7, passage du Vercors 69367 LYON CEDEX 07
E-mail : email@example.com; firstname.lastname@example.org